Envoy Medical Reports on First Quarter 2025 Results
- Secured $10 million in additional funding for pivotal clinical trial
- Successfully enrolled and partially activated participants in clinical trial with no serious adverse events
- Modifications appear to address previous electrical system noise issues
- Reduced G&A expenses by $284,000 compared to Q1 2024
- Revenue decreased due to battery replacement supply chain limitations
- Increased cost of goods sold by $73,000
- R&D expenses increased by $400,000
- Sales and marketing expenses increased by $33,000
Insights
Envoy Medical secured $10M funding for its implantable hearing device trial while reducing losses by 20% YoY despite ongoing cash burn.
Envoy Medical's Q1 2025 financial results reveal a company making progress on cost management while advancing its innovative hearing technology. The net loss improved to
The balance sheet shows
R&D expenses increased by
The company's debt position changed notably, with term loans payable to related parties increasing to
While the financial statements show a company still facing significant challenges, the improved loss metrics and additional funding provide important operational runway as Envoy advances its pivotal clinical study for the Acclaim cochlear implant.
Envoy's fully implanted cochlear implant shows promising early clinical results with 10 patients enrolled and no safety issues reported.
Envoy Medical has reached a significant milestone in the development of their Acclaim fully implanted cochlear implant with the completion of enrollment for 10 participants in the "first stage" of their pivotal clinical trial. Six participants have been activated (had their devices turned on), with the remaining four scheduled for activation in May. Importantly, two participants have already completed their 1-month follow-up assessments.
The safety profile appears favorable so far, with the company reporting no Serious Adverse Events or Unanticipated Adverse Device Effects in the trial participants. The company states that activations and follow-up visits have been "within expectations of 'typical' or 'normal' cochlear implant activations" over a similar timeframe, suggesting the novel fully implanted design is functioning as intended in these initial cases.
A noteworthy technical achievement is that modifications implemented between the Early Feasibility Study and this Pivotal Clinical Trial appear to have successfully addressed previously identified electrical system noise issues – a common challenge in implantable hearing technology that can affect sound quality and performance.
The Acclaim cochlear implant differentiates itself from conventional devices in several key ways: it's fully implanted with no external components, uses the ear's natural anatomy to capture sound rather than an external microphone, eliminates the need for an implanted magnet in the head, and provides multiple days of battery life with typical use. These features directly address quality-of-life limitations that affect conventional cochlear implant users.
The Acclaim CI received FDA Breakthrough Device Designation in 2019, indicating regulatory recognition of its potential to address unmet needs for individuals with severe to profound hearing loss. This designation can help expedite the review process if the clinical data supports eventual approval.
Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.
Financial and Corporate Highlights for First Quarter and to date:
Secured additional
$10 Million in funding to advance Pivotal Clinical Trial.Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.
Activated (i.e., turned on) six of 10 participants with remaining four participants due to be activated in May. Additionally, two participants completed 1-Month Follow-Up visits.
No reports of Serious Adverse Events or Unanticipated Adverse Device Effects.
Thus far, activations and follow-up visits have been reported to be within expectations of "typical" or "normal" cochlear implant activations and 1-month follow-up visits over a similar timeframe.
Modifications and mitigations put in place between Early Feasibility Study and Pivotal Clinical Trial appear to address previously discussed electrical system noise.
Brent Lucas, CEO of Envoy Medical commented: "We could not be more pleased with the positive progress of our pivotal clinical study and the reported excitement from the investigational sites. Enrollment of the first 10 patients happened quickly and efficiently, and we believe it is yet another indication that, if given the choice, a meaningful percentage of patients who are candidates for cochlear implants will be drawn to a fully implanted solution that uses the ear to pick up sound instead of a microphone, does not have an implanted magnet in the head, and has multiple days of battery life with typical use. We designed our fully implanted Acclaim cochlear implant with patient's quality of life and preferences in mind, and we are thrilled to see anecdotal reports coming back that people want what our device is designed to offer. Personally, I'm extremely excited about Envoy Medical's future and our position in the hearing industry."
Financial Results for the Quarter Ended March 31, 2025
Net revenues decreased
R&D expenses increased
Sales and marketing expenses increased
General and administrative expenses decreased
As of March 31, 2025 cash and cash equivalents were approximately
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the timing and results of IRB approvals, site documents, logistics or activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any institution or healthcare professionals in such trials; the Acclaim CI being the first to market fully implanted cochlear implant; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Relations:
Envoy Medical Investor Relations
InvestorRelations@envoymedical.com
Media Contact:
Media@envoymedical.com
ENVOY MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| March 31, 2025 | December 31, 2024 | ||||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash | $ | 5,312 | $ | 5,483 | |||
| Accounts receivable, net | 42 | 38 | |||||
| Other receivable | 23 | 780 | |||||
| Inventories | 1,657 | 1,708 | |||||
| Prepaid expenses and other current assets | 1,278 | 1,375 | |||||
| Total current assets | 8,312 | 9,384 | |||||
| Property and equipment, net | 1,220 | 1,275 | |||||
| Operating lease right-of-use asset (related party) | 853 | 879 | |||||
| Total assets | $ | 10,385 | $ | 11,538 | |||
| Liabilities and stockholders' deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,662 | $ | 1,652 | |||
| Accrued expenses | 5,057 | 4,416 | |||||
| Other current liabilities | 415 | 573 | |||||
| Forward purchase agreement warrant liability | 51 | 472 | |||||
| Product warranty liability, current portion | 265 | 282 | |||||
| Operating lease liability, current portion (related party) | 145 | 143 | |||||
| Total current liabilities | 7,595 | 7,538 | |||||
| Term loans payable (related party) | 23,106 | 18,716 | |||||
| Product warranty liability, net of current portion | 1,771 | 1,771 | |||||
| Operating lease liability, net of current portion (related party) | 778 | 802 | |||||
| Publicly traded warrant liability | 468 | 662 | |||||
| Other liability | 891 | 891 | |||||
| Total liabilities | 34,609 | 30,380 | |||||
| Commitments and contingencies (see Note 14) | |||||||
| Stockholders' deficit | |||||||
| Series A Preferred Stock, | - | - | |||||
| Class A Common Stock, | 2 | 2 | |||||
| Additional paid-in capital | 266,861 | 266,013 | |||||
| Accumulated deficit | (290,970 | ) | (284,734 | ) | |||
| Accumulated other comprehensive loss | (117 | ) | (123 | ) | |||
| Total stockholders' deficit | (24,224 | ) | (18,842 | ) | |||
| Total liabilities and stockholders' deficit | $ | 10,385 | $ | 11,538 | |||
ENVOY MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net revenues | $ | 46 | $ | 59 | |||
| Costs and operating expenses: | |||||||
| Cost of goods sold | 226 | 153 | |||||
| Research and development | 2,748 | 2,360 | |||||
| Sales and marketing | 358 | 325 | |||||
| General and administrative | 1,821 | 2,105 | |||||
| Total costs and operating expenses | 5,153 | 4,943 | |||||
| Operating loss | (5,107 | ) | (4,884 | ) | |||
| Other income (expense): | |||||||
| Change in fair value of forward purchase agreement put option liability | - | 103 | |||||
| Change in fair value of forward purchase agreement warrant liability | 421 | (262 | ) | ||||
| Change in fair value of publicly traded warrant liability | 194 | (1,177 | ) | ||||
| Interest expense, related party | (495 | ) | (36 | ) | |||
| Other expense, net | (11 | ) | (14 | ) | |||
| Total other income (expense), net | 109 | (1,386 | ) | ||||
| Net loss | (4,998 | ) | (6,270 | ) | |||
| Cumulative preferred dividends | (1,238 | ) | (1,365 | ) | |||
| Net loss attributable to common stockholders, basic and diluted | $ | (6,236 | ) | $ | (7,635 | ) | |
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.29 | ) | $ | (0.41 | ) | |
| Weighted-average Class A Common Stock outstanding, basic and diluted | 21,326,609 | 18,599,982 | |||||
| Other comprehensive income (loss): | |||||||
| Foreign currency translation adjustment | 6 | (1 | ) | ||||
| Other comprehensive income (loss) | 6 | (1 | ) | ||||
| Comprehensive loss | $ | (4,992 | ) | $ | (6,271 | ) | |
ENVOY MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Cash flows from operating activities | |||||||
| Net loss | $ | (4,998 | ) | $ | (6,270 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation | 61 | 34 | |||||
| Interest expense and amortization of debt discount on term loans payable (related party) | 495 | - | |||||
| Amortization of prepaid insurance | 247 | 270 | |||||
| Stock-based compensation | 160 | 123 | |||||
| Change in fair value of publicly traded warrant liability | (194 | ) | 1,177 | ||||
| Change in fair value of forward purchase agreement warrant liability | (421 | ) | 262 | ||||
| Change in fair value of forward purchase agreement put option liability | - | (103 | ) | ||||
| Change in operating lease right-of-use asset (related party) | 26 | 31 | |||||
| Change in inventory reserve | (23 | ) | 89 | ||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | (4 | ) | (119 | ) | |||
| Other receivable | 757 | 144 | |||||
| Inventories | 74 | (140 | ) | ||||
| Prepaid expenses and other current assets | (75 | ) | (56 | ) | |||
| Accounts payable | 10 | (641 | ) | ||||
| Operating lease liability (related party) | (22 | ) | (27 | ) | |||
| Accrued expenses | 199 | (357 | ) | ||||
| Product warranty liability | (17 | ) | (6 | ) | |||
| Other liability | - | - | |||||
| Net cash used in operating activities | (3,725 | ) | (5,589 | ) | |||
| Cash flows from investing activities | |||||||
| Purchases of property and equipment | (6 | ) | - | ||||
| Deposits on equipment not yet placed in service | - | (109 | ) | ||||
| Net cash used in investing activities | (6 | ) | (109 | ) | |||
| Cash flows from financing activities | |||||||
| Payments on insurance financing loans | (233 | ) | (257 | ) | |||
| Proceeds from the issuance of term loans (related party) | 5,000 | 5,000 | |||||
| Dividends paid to stockholders of Series A Preferred Stock | (1,213 | ) | - | ||||
| Proceeds from the sale of Common Stock associated with forward purchase agreement, net of transaction costs | - | 1,683 | |||||
| Net cash provided by financing activities | 3,554 | 6,426 | |||||
| Effect of exchange rate changes on cash | 6 | (1 | ) | ||||
| Net (decrease) increase in cash | (171 | ) | 727 | ||||
| Cash, beginning of period | 5,483 | 4,218 | |||||
| Cash, end of period | $ | 5,312 | $ | 4,945 | |||
| Supplemental disclosures of cash flow information: | |||||||
| Cash paid for interest | $ | 13 | $ | 14 | |||
| Non-cash investing and financing activities: | |||||||
| Accrued and unpaid dividends on Series A Preferred Stock | $ | 25 | $ | 1,365 | |||
| Financing of prepaid insurance | $ | 75 | $ | 65 | |||
| Warrants issued with term loans (related party) | $ | 688 | $ | - | |||
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250488
FAQ
What were the key financial results for Envoy Medical (COCH) in Q1 2025?
How is Envoy Medical's Acclaim cochlear implant clinical trial progressing?
How much funding did COCH secure for its pivotal clinical trial?
What are the main features of Envoy Medical's Acclaim cochlear implant?
What is the cash position of Envoy Medical (COCH) as of Q1 2025?
